192 related articles for article (PubMed ID: 27098820)
1. Multifactorial intervention to prevent cardiovascular disease in patients with early rheumatoid arthritis: protocol for a multicentre randomised controlled trial.
Svensson AL; Christensen R; Persson F; Løgstrup BB; Giraldi A; Graugaard C; Fredberg U; Blegvad J; Thygesen T; Hansen IM; Colic A; Bagdat D; Ahlquist P; Jensen HS; Hørslev-Petersen K; Sheetal E; Christensen TG; Svendsen L; Emmertsen H; Ellingsen T
BMJ Open; 2016 Apr; 6(4):e009134. PubMed ID: 27098820
[TBL] [Abstract][Full Text] [Related]
2. Long-term prognosis and quality of life in patients with early rheumatoid arthritis treated according to the 2015 ACR guideline (LELAND): protocol for a multicentre prospective observational study in Southern China.
Zhao J; Zhan T; Zhu J; Fan M; Huang Q; Ren H; Wu J; Yu Q; Lin J; Ouyang Q; An S; Yang M
BMJ Open; 2018 Nov; 8(11):e023798. PubMed ID: 30446575
[TBL] [Abstract][Full Text] [Related]
3. Impact of a magnetic resonance imaging-guided treat-to-target strategy on disease activity and progression in patients with rheumatoid arthritis (the IMAGINE-RA trial): study protocol for a randomized controlled trial.
Møller-Bisgaard S; Hørslev-Petersen K; Ejbjerg BJ; Boesen M; Hetland ML; Christensen R; Møller J; Krogh NS; Stengaard-Pedersen K; Østergaard M
Trials; 2015 Apr; 16():178. PubMed ID: 25896862
[TBL] [Abstract][Full Text] [Related]
4. Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis.
Klarenbeek NB; Koevoets R; van der Heijde DM; Gerards AH; Ten Wolde S; Kerstens PJ; Huizinga TW; Dijkmans BA; Allaart CF
Ann Rheum Dis; 2011 Oct; 70(10):1815-21. PubMed ID: 21813548
[TBL] [Abstract][Full Text] [Related]
5. Thyroid disorders in patients with newly diagnosed rheumatoid arthritis is associated with poor initial treatment response evaluated by disease activity score in 28 joints-C-reactive protein (DAS28-CRP): An observational cohort study.
Emamifar A; Hangaard J; Jensen Hansen IM
Medicine (Baltimore); 2017 Oct; 96(43):e8357. PubMed ID: 29069018
[TBL] [Abstract][Full Text] [Related]
6. Microalbuminuria in patients with rheumatoid arthritis.
Pedersen LM; Nordin H; Svensson B; Bliddal H
Ann Rheum Dis; 1995 Mar; 54(3):189-92. PubMed ID: 7748016
[TBL] [Abstract][Full Text] [Related]
7. The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis.
Tanaka Y; Smolen JS; Jones H; Szumski A; Marshall L; Emery P
Arthritis Res Ther; 2019 Jul; 21(1):164. PubMed ID: 31277720
[TBL] [Abstract][Full Text] [Related]
8. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.
Gaede P; Vedel P; Larsen N; Jensen GV; Parving HH; Pedersen O
N Engl J Med; 2003 Jan; 348(5):383-93. PubMed ID: 12556541
[TBL] [Abstract][Full Text] [Related]
9. Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews.
Scott DL; Ibrahim F; Farewell V; O'Keeffe AG; Ma M; Walker D; Heslin M; Patel A; Kingsley G
Health Technol Assess; 2014 Oct; 18(66):i-xxiv, 1-164. PubMed ID: 25351370
[TBL] [Abstract][Full Text] [Related]
10. Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial.
Ruscitti P; Masedu F; Alvaro S; Airò P; Battafarano N; Cantarini L; Cantatore FP; Carlino G; D'Abrosca V; Frassi M; Frediani B; Iacono D; Liakouli V; Maggio R; Mulè R; Pantano I; Prevete I; Sinigaglia L; Valenti M; Viapiana O; Cipriani P; Giacomelli R
PLoS Med; 2019 Sep; 16(9):e1002901. PubMed ID: 31513665
[TBL] [Abstract][Full Text] [Related]
11. The new 2010 ACR/EULAR criteria as predictor of clinical and radiographic response in patients with early arthritis.
Mueller RB; Schiff M; Kaegi T; Finckh A; Haile SR; Schulze-Koops H; von Kempis J;
Clin Rheumatol; 2015 Jan; 34(1):51-9. PubMed ID: 25024096
[TBL] [Abstract][Full Text] [Related]
12. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study.
Smolen JS; Pangan AL; Emery P; Rigby W; Tanaka Y; Vargas JI; Zhang Y; Damjanov N; Friedman A; Othman AA; Camp HS; Cohen S
Lancet; 2019 Jun; 393(10188):2303-2311. PubMed ID: 31130260
[TBL] [Abstract][Full Text] [Related]
13. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate.
Wells G; Becker JC; Teng J; Dougados M; Schiff M; Smolen J; Aletaha D; van Riel PL
Ann Rheum Dis; 2009 Jun; 68(6):954-60. PubMed ID: 18490431
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA).
Burmester GR; Feist E; Kellner H; Braun J; Iking-Konert C; Rubbert-Roth A
Ann Rheum Dis; 2011 May; 70(5):755-9. PubMed ID: 21187298
[TBL] [Abstract][Full Text] [Related]
15. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial.
Ueki K; Sasako T; Okazaki Y; Kato M; Okahata S; Katsuyama H; Haraguchi M; Morita A; Ohashi K; Hara K; Morise A; Izumi K; Ishizuka N; Ohashi Y; Noda M; Kadowaki T;
Lancet Diabetes Endocrinol; 2017 Dec; 5(12):951-964. PubMed ID: 29079252
[TBL] [Abstract][Full Text] [Related]
16. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
[TBL] [Abstract][Full Text] [Related]
17. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
Cañete JD; Suárez B; Hernández MV; Sanmartí R; Rego I; Celis R; Moll C; Pinto JA; Blanco FJ; Lozano F
Ann Rheum Dis; 2009 Oct; 68(10):1547-52. PubMed ID: 18930989
[TBL] [Abstract][Full Text] [Related]
18. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study.
Vermeer M; Kuper HH; Hoekstra M; Haagsma CJ; Posthumus MD; Brus HL; van Riel PL; van de Laar MA
Arthritis Rheum; 2011 Oct; 63(10):2865-72. PubMed ID: 21647867
[TBL] [Abstract][Full Text] [Related]
19. Impact of a multifactorial treatment programme on clinical outcomes and cardiovascular risk estimates: a retrospective cohort study from a specialised diabetes centre in Denmark.
Safai N; Carstensen B; Vestergaard H; Ridderstråle M
BMJ Open; 2018 Mar; 8(3):e019214. PubMed ID: 29550776
[TBL] [Abstract][Full Text] [Related]
20. Effect of a 12-week high-intensity exercise intervention: a comparison of cardiac exercise adaptations during biological disease-modifying antirheumatic drug treatment (TNF inhibitors vs IL-6 signalling inhibitors) in patients with rheumatoid arthritis - study protocol for a randomised controlled trial.
Jønck S; Adamsen ML; Højgaard P; Rasmussen IE; Ellingsgaard H; Lund MAV; Jørgensen PG; Jacobsen S; Køber L; Vejlstrup N; Dreyer L; Pedersen BK; Berg RMG; Christensen RH
BMJ Open; 2023 May; 13(5):e068600. PubMed ID: 37169504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
